9Mes·

Healthcare sector thus also covered and most convinced by J&J🙈🐵

10.09
Johnson&Johnson logo
Acquistato x7 a 152,56 €
1067,94 €
27
6 Commenti

immagine del profilo
For what reason J&J?
2
immagine del profilo
@Tojasoku I would be interested in that too. I would also be interested to know who was in the comparison group and why they decided against others🤔
1
immagine del profilo
J&J had a strong correction has now recovered already 2% divi + strong growth in my eyes and in my opinion they have no more hurdles ahead of them in the near future and will grow solidly. Novo nordisk & CVS health were still in the selection...
immagine del profilo
@Jico Have you looked further into the products? It's always interesting to see what's in the pipeline, especially with pharmaceuticals.
immagine del profilo
Not every sector has to be covered. Pharma is difficult. You either have to be able to assess the pipeline quite well and still move in highly speculative spheres or you have enormously sporty valued companies in front of your nose or, as in the case of Johnson & Johnson, a blue chip portfolio brake with only moderate growth and the constant danger of slipping into some pharmaceutical scandal.
1
immagine del profilo
J&j falls. Abott and Amgen are more stable
Partecipa alla conversazione